-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Analyst Ratings for Karyopharm Therapeutics
Analyst Ratings for Karyopharm Therapeutics
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter:
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 1 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 1 | 0 | 0 |
In the last 3 months, 5 analysts have offered 12-month price targets for Karyopharm Therapeutics. The company has an average price target of $9.0 with a high of $16.00 and a low of $5.00.
Below is a summary of how these 5 analysts rated Karyopharm Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average is unchanged from the previous average price target.
Stay up to date on Karyopharm Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Analyst Ratings: What Are They?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Analysts have provided the following ratings for Karyopharm Therapeutics (NASDAQ:KPTI) within the last quarter:
分析師在上個季度對卡育藥療法(NASDAQ:KPTI)提供了以下評級:
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 1 | 0 | 1 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 1 | 0 | 0 |
牛市看漲 | 有點看漲 | 冷漠 | 有點看跌 | 看跌 | |
---|---|---|---|---|---|
總評分 | 1 | 2 | 2 | 0 | 0 |
最後 30 天 | 0 | 1 | 0 | 0 | 0 |
1 米前 | 1 | 0 | 1 | 0 | 0 |
2 小時前 | 0 | 0 | 0 | 0 | 0 |
3 分鐘前 | 0 | 1 | 1 | 0 | 0 |
In the last 3 months, 5 analysts have offered 12-month price targets for Karyopharm Therapeutics. The company has an average price target of $9.0 with a high of $16.00 and a low of $5.00.
在過去的 3 個月中,5 位分析師為 Karyopharm 治療提供了 12 個月的價格目標。該公司的平均目標價為 9.0 美元,高位為 16.00 美元,低點為 5.00 美元。
Below is a summary of how these 5 analysts rated Karyopharm Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
以下是這 5 位分析師如何評價 Karyopharm 治療在過去 3 個月的摘要。看漲評級的數量越多,對股票的積極分析師越多,看跌評級的數量越大,對股票的負面分析師就越多
This current average is unchanged from the previous average price target.
該當前平均價格與之前的平均價格目標不變。
Stay up to date on Karyopharm Therapeutics analyst ratings.
了解 Karyopharm 治療分析師評級的最新信息。
If you are interested in following small-cap stock news and performance you can start by tracking it here.
如果您對關注小型股票新聞和表現感興趣,可以從此處進行跟踪開始。
Analyst Ratings: What Are They?
分析師評級:它們是什麼?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Beninga 跟踪 150 家分析師公司並報告他們的股票期望。分析師通常通過預測一家公司在未來(通常是即將到來的五年)賺多少錢,以及該公司的收入來源的風險或可預測性的風險來得出結論。
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
分析師參加公司電話會議和會議,研究公司財務報表,並與內部人員進行溝通,以發布他們對股票的評級。分析師通常每個股票每季一次或每當公司有重大更新時對每隻股票進行評分。
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
一些分析師還提供有用指標的預測,例如收入,收入和增長估計,以提供有關如何處理某些股票代碼的進一步指導。重要的是要記住,儘管股票和行業分析師是專家,但他們也是人類的,只能向交易者預測自己的信念。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由 Beninga 的自動化內容引擎生成,並由編輯審查。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧